Susan E. Minton, DO

BOARD CERTIFICATION:
          •  Medical Oncology

FELLOWSHIP:
          •  University of South Florida - Hematology & Oncology

RESIDENCY:
          •  University of Florida Health Science Center of Jacksonville - Internal Medicine

MEDICAL SCHOOL:
          •  University of Medicine & Dentistry of New Jersey - MD

• Phillips KM, McGinty HL, Gonzalez BD, Jim HS, Small BJ, Minton S, Andrykowski MA, Jacobsen PB. Factors associated with breast cancer worry 3 years after completion of adjuvant treatment. Psychooncology. 2013 Apr;22(4):936-939. Pubmedid: 22419546. Pmcid: PMC3392435.


• Silva AS, Kam Y, Khin ZP, Minton SE, Gillies RJ, Gatenby RA. Evolutionary approaches to prolong progression-free survival in breast cancer. Cancer Res. 2012 Dec;72(24):6362-6370. Pubmedid: 23066036. Pmcid: PMC3525750.


• Jim HS, Small BJ, Minton S, Andrykowski M, Jacobsen PB. History of major depressive disorder prospectively predicts worse quality of life in women with breast cancer. Ann Behav Med. 2012 Jun;43(3):402-408. Pubmedid: 22167580. Pmcid: PMC3424106.


• Munster PN, Moore AP, Ismail-Khan R, Cox CE, Lacevic M, Gross-King M, Xu P, Carter WB, Minton SE. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol. 2012 Feb;30(5):533-538. Pubmedid: 22231041. Pmcid: PMC3295555.


• Bardhan P, Bui MM, Minton S, Loftus L, Carter WB, Laronga C, Ismail-Khan R. HER2-positive male breast cancer with thyroid cancer: an institutional report and review of literature. Ann Clin Lab Sci. 2012;42(2):135-139. Pubmedid: 22585608.


• Haviland R, Eschrich S, Bloom G, Ma Y, Minton S, Jove R, Cress WD. Necdin, a Negative Growth Regulator, Is a Novel STAT3 Target Gene Down-Regulated in Human Cancer. PLoS One. 2011 Oct;6(10):e24923. Pubmedid: 22046235.


• Kiluk JV, Lee MC, Park CK, Meade T, Minton S, Harris E, Kim J, Laronga C. Male Breast Cancer: Management and Follow-up Recommendations. Breast J. 2011 Sep;17(5):503-509. Pubmedid: 21883641.


• Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 2011 Jun;104(12):1828-1835. Pubmedid: 21559012. Pmcid: PMC3111195.


• Faul LA, Jim HS, Minton S, Fishman M, Tanvetyanon T, Jacobsen PB. Relationship of exercise to quality of life in cancer patients beginning chemotherapy. J Pain Symptom Manage. 2011 May;41(5):859-869. Pubmedid: 21330097.


• Robert NJ, Saleh MN, Paul D, Generali D, Gressot L, Copur MS, Brufsky AM, Minton SE, Giguere JK, Smith JW, Richards PD, Gernhardt D, Huang X, Liau KF, Kern KA, Davis J. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial. Clin Breast Cancer. 2011 Apr;11(2):82-92. Pubmedid: 21569994.


• Munster P, Marchion D, Bicaku E, Lacevic M, Kim J, Centeno B, Daud A, Neuger A, Minton S, Sullivan D. Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC. Clin Cancer Res. 2009 Apr;15(7):2488-2496. Pubmedid: 19318486.


• Moulder S, Valkov N, Neuger A, Choi J, Lee JH, Minton S, Munster P, Gump J, Lacevic M, Lush R, Sullivan D. Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response. Cancer. 2008 Nov;113(10):2646-2654. Pubmedid: 18823053.


• M?nster P, Marchion D, Bicaku E, Schmitt M, Lee JH, DeConti R, Simon G, Fishman M, Minton S, Garrett C, Chiappori A, Lush R, Sullivan D, Daud A. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol. 2007 May;25(15):1979-1985. Pubmedid: 17513804.


• Munster PN, Britten CD, Mita M, Gelmon K, Minton SE, Moulder S, Slamon DJ, Guo F, Letrent SP, Denis L, Tolcher AW. First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors. Clin Cancer Res. 2007 Feb;13(4):1238-1245. Pubmedid: 17317835.


• Munster P, Britten C, Mita M, Gelmon K, Minton S, Moulder S, Slamon D, Guo F, Letrent S, Denis L, Tolcher A. First Study of the Safety, Tolerability, and Pharmacokinetics of CP-724,714 in Patients with Advanced Malignant Solid HER2-Expressing Tumors. Clin Cancer Res. 2007 Feb;13(4):1238-1245. Pubmedid: 173.


• Cox C, Cox J, White L, Stowell N, Clark J, Allred N, Meyers M, Dupont E, Furman B, Minton S. Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer. Ann Surg Oncol. 2006 Apr;13(4):483-490. Pubmedid: 16523361.


• Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M, Nam S, Eweis I, Diaz N, Sullivan D, Yoder S, Enkemann S, Eschrich S, Lee JH, Beam CA, Cheng J, Minton S, Muro-Cacho CA, Jove R. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res. 2006 Jan;12(1):11-19. Pubmedid: 16397018.


• Diaz N, Minton S, Cox C, Bowman T, Gritsko T, Garcia R, Eweis I, Wloch M, Livingston S, Seijo E, Cantor A, Lee JH, Beam CA, Sullivan D, Jove R, Muro-Cacho CA. Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res. 2006 Jan;12(1):20-28. Pubmedid: 16397019.


• Kumar N, Allen K, Riccardi D, Bercu B, Cantor A, Minton S, Balducci L, Jacobsen P. Fatigue, weight gain, lethargy and amenorrhea in breast cancer patients on chemotherapy: is subclinical hypothyroidism the culprit. Breast Cancer Res Treat. 2004;83(2):149-159. Pubmedid: 14997046.


• Minton S, Munster P. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control. 2002;9(6):466-472. Pubmedid: 12514564.


• Weitzner M, Moncello J, Jacobsen P, Minton S. A pilot trial of paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer. J Pain Symptom Manage. 2002;23(4):337-345. Pubmedid: 11997203.


• Minton S, Munster P. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control. 2002;9(6):466-471. Pubmedid: 12514564.


• Garcia R, Bowman T, Niu G, Minton S, Muro-Cacho C, Cox C, Kraker A, Levitzki A, Parsons S, Jove R, Falcone R, Fairclough R, Yu H, Laudano A, Gazit A. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene. 2001;20(20):2499-2513. Pubmedid: 11420660.


• Minton S. Chemoprevention of breast cancer in the older patient. Hematol Oncol Clin North Am. 2000;14(1):113-129. Pubmedid: 10680075.


• Sutphen R, Diamond T, Minton S, Peacocke M, Root A. Severe Lhermitte-Duclos disease with unique germline mutation of PTEN. Am J Med Genet. 1999;82(4):290-293. Pubmedid: 10051160.


• Minton S. Breast cancer treatment: prospects for the future. Cancer Control. 1999;6:215-217. Pubmedid: 10758551.


• Minton S. New hormonal therapies for breast cancer. Cancer Control. 1999;6(3):247-255. Pubmedid: 10758554.


• Lyman G, Kuderer N, Lyman S, Debus M, Minton S, Balducci L, Horton J, Reintgen D, Cox C. Menopausal status and the impact of early recurrence on breast cancer survival. Cancer Control. 1997;4(4):335-341. Pubmedid: 10763039.


• Minton S, Shaw G. Chemoprevention of cancer in the elderly. In: Balducci L, Lyman G, Ershler W, et al, eds. Comprehensive Geriatric Oncology. Harwood Academic Publishers; 1998;307-324.

Dr. Susan Minton is a medical oncologist specializing in breast cancer in The Center for Women’s Oncology at Moffitt Cancer Center.  She has been a Moffitt physician for more than a decade and seves as the Clinical Director of Breast Medial Oncology.

Dr. Minton treats women of all ages and stages of breast disease, but her special interest is pre-menopausal women.  She sees patients at Moffitt Cancer Center in the USF area and at Moffitt Cancer Center at International Plaza.

Translational research is another area of concentration for Dr. Minton and she chairs the Breast Program Clinical Research Committee.  Her primary focus is chemo-prevention studies and phase one experimental trials looking at protein-based targeted therapies for breast cancer.  In addition, she is the medical director of research compliance, a Moffitt committee that monitors clinical trials to ensure their safety and quality.

Dr. Minton enjoys serving as a mentor for junior faculty members and physicians pursuing oncology fellowship training.  She has been a member of the National Comprehensive Cancer Network breast cancer screening and prevention committees and is currently an ad hoc reviewer for the Journal of Clinical Oncology and Cancer Investigation.

Dr. Minton has been named one of Tampa Bay’s “Best Doctors” every year since 2005. 

She is a frequent speaker at community forums and professional conferences, and has published extensively on breast cancer topics in medical journals.